Drug-Eluting Stents Dominate Coronary Market, For Now

PR Log (Press Release) – Sep 09, 2009 – The global market for coronary stents is owned largely by drug-eluting stents (DES), but the size of the patient pool, the drive for lowered cost, ever-increased efficacy and less trauma are spawning the development of multiple new technologies in coronary stents and competitive anti-restenosis technologies. The global market, products, companies, trends and opportunities are the subject of the 2009 report, "Worldwide Coronary Stents 2009,"  from MedMarket Diligence.

In 2009, drug-eluting stents (DES) command 60% of typical markets for coronary stents and, in some markets like China, the share is much higher.  Growth in the market for DES, at over 7%, is more than twice what it is for bare metal stents, since DES have demonstrated, through anti-restenosis, the ability to considerably reduced the need for repeat revascularization. The market for coronary stents will therefore continue to grow, penetrating deeper into bare metal stent markets and furthering the erosion of demand for the more invasive surgical alternative, coronary artery bypass grafting.

"The number of active companies and the size and growth of the market for coronary stents speaks to the intensity of development," says Patrick Driscoll of MedMarket Diligence, publisher of the report, 'Worldwide Coronary Stents Market, 2009'.  At least 75 companies are active in this arena, with current products on the market or at various stages of development.  Few avenues are being overlooked in development, from stent material types, stent surface technology, drug-coating alternatives, drug-coating processes and others.  

Development of stent alternatives also includes bioabsorbable stents, which may be the likely successor to drug-eluting stents if they achieve the goal of providing revascularization with markedly better long-term clinical outcomes. Bioabsorbales under development may well enter some markets as soon as two years from now.  

Moreover, the premise of drug-eluting stents is being challenged through alternatives like drug-eluting balloon angioplasty and other device and non-device alternatives.  

The MedMarket Diligence report #C245 is described at http://www.mediligence.com/rpt/rpt-c245.htm and details the worldwide market for the use of alternative stent devices in the treatment of coronary artery disease.  The report assesses the treatment of coronary artery disease by alternative treatment methodologies (percutaneous intervention with or without stenting, coronary artery bypass grafting alternatives and other medical/surgical treatment options), with estimated current/forecast caseload across treatment types. 

The report provides full year (actual) 2008 market size and share data, with forecast market data to 2017, for the U.S., Europe, Asia/Pacific and Rest of World.

The report details currently approved coronary stents, providing data on current and forecast impact on the market.  The report also details the current state of product development in bare stents, drug-coated or drug-eluting stents and bioabsorbable stents in coronary applications and details the products under development, the anticipated timeline and impact of their market introduction.  The report assesses the current and ten-year forecast global market for coronary stents, with segmentation by U.S., Europe, Asia/Pacific and Rest of World.  The report provides competitor market shares by these geographic regions.  The leading and key emerging coronary stent manufacturers are profiled with current product offerings, development status and market strengths/advantages.